Skip to main content

Advertisement

SpringerLink
Log in

Immunologist’s Perspectives on Assessment and Management of Lung Disease in CVID: a Survey of the Membership of the Clinical Immunology Society and the European Society for Immunodeficiencies

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372(9637):489–502.

    Article  PubMed  Google Scholar 

  2. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38–59.

    Article  PubMed  Google Scholar 

  3. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93(3):190–7.

    Article  CAS  PubMed  Google Scholar 

  5. Immune Deficiency Foundation. IDF annual report. Towson, MD; 2012 Contract No.: Document Number|.

  6. Adams PF, Kirzinger WK, Martinez ME. Summary health statistics for the U.S. population: national health interview survey. Vital Health Stat 10. 2011;2012(255):1–110.

    Google Scholar 

  7. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.

    Article  PubMed  Google Scholar 

  8. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.

    PubMed  Google Scholar 

  9. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis in adults: diagnosis and management. NICE Guideline (CG163). 2013.

  10. Hernandez-Trujillo VP, Scalchunes C, Hernandez-Trujillo HS, Boyle J, Williams P, Boyle M, et al. Primary immunodeficiency diseases: an opportunity in pediatrics for improving patient outcomes. Clin Pediatr (Phila). 2015;54(13):1265–75.

    Article  Google Scholar 

  11. Orange JS, Akhter J, Seeborg FO, Boyle M, Scalchunes C, Hernandez-Trujillo V. Pulmonologist perspectives regarding diagnosis and management of primary immunodeficiency diseases. Allergy Asthma Proc. 2016;37(6):162–8.

    Article  PubMed  Google Scholar 

  12. Orange JS, Seeborg FO, Boyle M, Scalchunes C, Hernandez-Trujillo V. Family physician perspectives on primary immunodeficiency diseases. Front Med (Lausanne). 2016;3:12.

    Google Scholar 

  13. Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255–63.

    Article  CAS  PubMed  Google Scholar 

  14. Maarschalk-Ellerbroek LJ, de Jong PA, van Montfrans JM, Lammers JW, Bloem AC, Hoepelman AI, et al. CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters. J Clin Immunol. 2014;34(6):642–54.

    Article  CAS  PubMed  Google Scholar 

  15. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9.

    Article  CAS  PubMed  Google Scholar 

  16. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008;102(10):1494–6.

    Article  CAS  PubMed  Google Scholar 

  17. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4(2):117–22.

    Article  CAS  PubMed  Google Scholar 

  18. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2(12):988–96.

    Article  CAS  PubMed  Google Scholar 

  19. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–7.

    Article  CAS  PubMed  Google Scholar 

  20. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–7.

    Article  CAS  PubMed  Google Scholar 

  21. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–65.

    Article  CAS  PubMed  Google Scholar 

  22. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2(9):738–49.

    Article  CAS  PubMed  Google Scholar 

  23. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–82.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Sugianto TD, Chan HK. Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opin Drug Deliv. 2016;13(1):7–22.

    Article  CAS  PubMed  Google Scholar 

  25. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(5):1086–92.

    Article  CAS  PubMed  Google Scholar 

  26. Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis. 2007;4(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  27. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106(5):661–7.

    Article  PubMed  Google Scholar 

  28. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113(5):1329–34.

    Article  PubMed  Google Scholar 

  29. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med. 1996;154(2 Pt 1):413–7.

    Article  CAS  PubMed  Google Scholar 

  30. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 Suppl):1S–39S.

    Article  PubMed  Google Scholar 

  31. Boursiquot JN, Gerard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol. 2013;33(1):84–95.

    Article  CAS  PubMed  Google Scholar 

  32. Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2017;5(4):938–45.

    Article  PubMed  Google Scholar 

  33. Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013;33(1):30–9.

    Article  CAS  PubMed  Google Scholar 

  34. Mera-Varela A, Perez-Pampin E. Abatacept therapy in rheumatoid arthritis with interstitial lung disease. J Clin Rheumatol. 2014;20(8):445–6.

    Article  PubMed  Google Scholar 

  35. Nakashita T, Ando K, Takahashi K, Motojima S. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016;54(5):376–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advocate Children’s Hospital, Oak Lawn, IL, USA

    Javeed Akhter, Cheryl A. Lefaiver & Michael DiGirolamo

  2. Immune Deficiency Foundation, Towson, MD, USA

    Christopher Scalchunes

  3. Centre for Chronic Immunodeficiency, Freiburg, Germany

    Klaus Warnatz

Authors
  1. Javeed Akhter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheryl A. Lefaiver
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Scalchunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael DiGirolamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klaus Warnatz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javeed Akhter.

Ethics declarations

Conflicts of Interest

None of the authors received money or other reimbursement for their work on this project or have conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akhter, J., Lefaiver, C.A., Scalchunes, C. et al. Immunologist’s Perspectives on Assessment and Management of Lung Disease in CVID: a Survey of the Membership of the Clinical Immunology Society and the European Society for Immunodeficiencies. J Clin Immunol 38, 237–246 (2018). https://doi.org/10.1007/s10875-018-0488-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-018-0488-9

Search

Navigation